Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib maintenance after definitive platinum-based chemoradiotherapy in unresectable EGFR-mutant stage III non-small cell lung cancer
CTR20190036Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190036.